# Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy

> **NCT01498887** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 347 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Fingolimod (FTY720)

## Key facts

- **NCT ID:** NCT01498887
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-24
- **Primary completion:** 2015-12-26
- **Final completion:** 2015-12-26
- **Target enrollment:** 347 (ACTUAL)
- **Last updated:** 2019-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01498887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01498887, "Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01498887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*